Longboard Pharmaceuticals
Clinical trials sponsored by Longboard Pharmaceuticals, explained in plain language.
-
New drug trial offers hope for controlling severe seizures in rare genetic disorder
Disease control Recruiting nowThis study is testing whether the experimental drug LP352 can safely reduce seizure frequency in people with Dravet syndrome, a rare and severe form of epilepsy. The trial will involve 160 children and adults who will receive either LP352 or a placebo for approximately 24 months.…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for severe childhood epilepsy: experimental drug enters final testing phase
Disease control Recruiting nowThis study is testing whether an investigational drug called LP352 can safely reduce seizure frequency in children and adults with severe developmental and epileptic encephalopathies (DEE). Researchers will compare LP352 against a placebo in about 320 participants over approximat…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC